Retinal Vein Occlusion: A Review of Current Thinking

This supplement is a write-up of a promotional meeting organised and funded by Bayer. The speakers were paid honoraria toward the meeting. Bayer checked the content for factual accuracy, to ensure it is fair and balanced, and it complies with the ABPI Code of Practice. The views and opinions of the speakers are not necessarily those of Bayer or the publisher. No part of this publication may be reproduced in any form without the permission of the publisher. Catherine Creuzot-Garcher MD, PhD, FEBO, professor and chair at University Hospital, Dijon,France, chaired Bayer Satellite Symposium “Retinal Vein Occlusion” held on 18 September 2015 at the 15th EURETINA Congress in Nice, France. In her introductory remarks, Prof. Creuzot-Garcher reminded her audience that retinal vein occlusion (RVO) is the second most common cause of vision loss from retinal vascular disease after diabetic retinopathy, with an estimated 16.4 million people affected by RVO worldwide.14 “RVO is associated with significant personal and societal burdens. It will induce visual impairment and blindness which are responsible for $8 billion in lost productivity every year.1 The disease also has a significant negative impact on the quality of life of our patients. In 11 out of 12 subdomains identified in quality-of-life questionnaires,2 people with RVO had significantly worse scores than those of a reference group without ocular disease,” she said. Download Supplement - click here